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Background: Sun ginseng (SG), a speciﬁc formulation of quality-controlled red ginseng, contains
approximately equal amounts of three major ginsenosides (RK1, Rg3, and Rg5), which reportedly has
antitumor-promoting activities in animal models.
Methods: MTT assay was used to assess whether SG can potentiate the anticancer activity of epirubicin or
paclitaxel in human cervical adenocarcinoma HeLa cells, human colon cancer SW111C cells, and SW480
cells; apoptosis status was analyzed by annexin V-FITC and PI and analyzed by ﬂow cytometry; and
apoptosis pathway was studied by analysis of caspase-3, -8, and -9 activation, mitochondrial accumu-
lation of Bax and Bak, and cytochrome c release.
Results: SG remarkably enhances cancer cell death induced by epirubicin or paclitaxel in human cervical
adenocarcinoma HeLa cells, human colon cancer SW111C cells, and SW480 cells. Results of the mech-
anism study highlighted the cooperation between SG and epirubicin or paclitaxel in activating caspase-3
and -9 but not caspase-8. Moreover, SG signiﬁcantly increased the mitochondrial accumulation of both
Bax and Bak triggered by epirubicin or paclitaxel as well as the subsequent release of cytochrome c in the
targeted cells.
Conclusion: SG signiﬁcantly potentiated the anticancer activities of epirubicin and paclitaxel in a syn-
ergistic manner. These effects were associated with the increased mitochondrial accumulation of both
Bax and Bak that led to an enhanced cytochrome c release, caspase-9/-3 activation, and apoptosis.
Treating cancer cells by combining epirubicin and paclitaxel with SG may prove to be a novel strategy for
enhancing the efﬁcacy of the two drug types.
Copyright  2014, The Korean Society of Ginseng, Published by Elsevier. All rights reserved.1. Introduction
Cancer is one of the most fatal diseases that poses a threat to
human health worldwide [1]. A deviant regulation of apoptosis is
required for cancer initiation, development, and metastasis [2].
Recent anticancer treatment, including chemotherapy, immuno-
therapy, radiation, and cytokines, primarily induce apoptosis in
targeted cancer cells [3]. Apoptosis, a programmed cell death, is
initiated through two main pathways: the exogenous pathway,
which is characterized by death receptor activation; and the
endogenous pathway, which is characterized by mitochondriallar Enzymology, Engineering of th
il.net (Y.-H. Jin).
rk.
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e Korean Society of Ginseng, Publdestruction [4]. The tumor necrosis factor receptor superfamily
triggers the membrane receptor aggregation and then recruits Fas
associated death domain (FADD) and caspase-8 by binding of its
speciﬁc ligand. Upon recruitment, caspase-8 becomes activated and
initiates apoptosis through the direct cleavage of the downstream
effector caspases, particularly caspase-3 and -7. In the mitochon-
drial pathway, apoptogenic factors, such as cytochrome c, second
mitochondria-derived activator of caspases (Smac), or apoptosis-
inducing factor (AIF), are released into the cytosol from the mito-
chondria. Cytochrome c triggers the activation of caspase-9 by
forming the cytochrome c/apoptotic protease-activating factore Ministry of Education, Jilin University, 2699 Qianjin Street, Changchun 130012,
tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)
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Smac promotes the activation of caspase by invaliding the inhibi-
tory effects of the inhibitors of apoptosis (IAP) family [5e7]. Com-
bination treatments prove to be advantageous in treating
malignancies that still partially respond to a single treatment [8].
Drugs have long been combined to treat diseases and reduce
suffering; this long-standing history of drug combinations is clearly
depicted in traditional Chinese medicines [9].
Panax ginseng has been long used for several thousand years in
the Orient as a tonic, prophylactic, and restorative agent [10]. Sun
ginseng (SG), a new type of ginseng that is processed by heating at
speciﬁc pressures, contains approximately equal amounts of three
major ginsenosides (RK1, Rg3, and Rg5). SG reportedly serves
several functions, including radical scavenging and antitumor-
promoting activities [11e13]. Ginsenoside Rg3, one of the most
studied of the three major ginsenosides, is reported to inhibit the
proliferation, migration, and invasion in many common cancers,
such as liver, prostate, colorectal, and ovarian, and has been widely
used in cancer treatment [14e17]. Rg3 can induce apoptosis and
cell cycle arrest in different cancer cells via different pathways such
as downregulating hypoxia inducible factor-1 (HIF-1) and vascular
endothelial growth factor (VEGF) [18e21]. Rk1 was investigated to
inhibit telomerase activity and cell growth and induce apoptosis
through activation of caspase-8 and -3 via ERK pathway, whereas
another article demonstrated that Rk1 could induce G1 arrest and
autophagy [22,23]. Rg5 blocks the cell cycle at the Gl/S transition
phase by increasing p21Cip/WAF1 and decreasing cyclin E and
CDK2 [24].
Epirubicin is a third-generation anthracycline that treats a
broad spectrum of cancers, including cervical, breast, lung
(especially small cell lung cancer), ovarian, stomach, colon, and
bladder, and malignant lymphoma [25,26]. Similar to widely used
anticancer drugs, epirubicin exhibits some adverse effects on
blood, the stomach, and the heart; these effects largely depend
on the applied doses [27]. Paclitaxel is another important anti-
cancer drug that is widely used as a chemotherapeutic agent for
treating ovarian, breast, lung, colorectal, bladder, prostate, and
gastric cancer, melanoma, and lymphoma [28e30]. Paclitaxel,
which is an inhibitor of microtubule degradation, induces cell
cycle arrest at the G2/M phase [31,32] and ultimately apoptosis
[33,34]. This drug also has signiﬁcant adverse effects, such as
hypersensitivity, neutropenia syndrome, neurotoxicity, heart
rhythm disorders, and intracellular toxicity [35e37]. Therefore,
developing adjuvant agents to potentiate the anticancer activities
of epirubicin and paclitaxel and to minimize their adverse effects
is signiﬁcant.
In the current study, SG signiﬁcantly potentiated the anticancer
activities of epirubicin and paclitaxel in a synergistic manner. These
effects were associated with the increased mitochondrial accu-
mulation of both Bax and Bak that led to an enhanced cytochrome c
release, caspase-9/-3 activation, and apoptosis.
2. Materials and methods
2.1. Materials
SG was provided by Dr. Jeong Hill Park, College of Pharmacy,
Seoul National University, Seoul, Korea. 3-(4, 5-dimethylthiazol-2-
yl)-2, 5-diphenyltetrazolium bromide (MTT), and dimethylsulf-
oxide (DMSO) were purchased from SigmaeAldrich (St. Louis, MO,
USA). Epirubicin was acquired from Pﬁzer (Wuxi, China). Newborn
calf serum and Dulbecco modiﬁed Eagle’s medium (DMEM) were
purchased from Gibco (Life Technologies, Grand Island, NY, USA).
Caspase substrates Ac-DEVD-AFC, Ac-IETD-AFC, and Ac-LEHD-AFC
were purchased from Calbiochem (La Jolla, CA, USA). TheMitochondria Isolation Kit was purchased from Pierce (Rockford, IL,
USA). Annexin V-FITC Apoptosis Detection Kit was purchased from
KeyGEN Biotech (Nanjing, China). Polyvinylidene diﬂuoride (PVDF)
membrane was purchased from Millipore (Billerica, MA, USA).
Antibodies against cytochrome c, poly (adenosine diphosphate-
ribose) polymerase (PARP), Bak, Bax, a-tubulin were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies
against caspase-8, -9, and cytochrome c oxidase II (Cox II) were
purchased from Cell Signaling Technology (Beverly, MA, USA).
Clarity Western ECL Substrate Kit was purchased from Bio-Rad
(Hercules, CA, USA).
2.2. Cell culture
HeLa, SW111C, and SW480 cells were grown in DMEM supple-
mented with 10% (by volume) heat-inactivated newborn calf
serum,100 mg/mL of streptomycin 100 U/mL of penicillin, at 37C in
a humidiﬁed atmosphere with 5% CO2.
2.3. Analysis of SG methanol extract
The SG methanol extract was analyzed as a previous report
described [38]. Brieﬂy, SG was dissolved in MeOH (3 mg/mL), and
ﬁltered with 0.45mmMillipore ﬁlter, and the solution was analyzed
with a Waters 2695 liquid chromatograph (Waters Corporation,
Milford, MA, USA) ﬁtted with Knauer C-18, reverse-phase column
(Knauer, Berlin, Germany; 5mm,4250 mm  3 mm) utilizing the
solvent gradient system. The mobile phase consisted of acetonitrile
water (Solvent A) and water (Solvent B) and the ﬂow rate was
0.6 mL/min. The detector was a Waters 2996 PDA Detector (Waters
Corporation). The gradient elution was used as follows: 0e20 min,
20% A; 20e31 min, linear gradient from 20e32% A; 31e40 min,
linear gradient from 32e43% A; 40e70 min, linear gradient from
43e100% A; and 70 min, 100% A.
2.4. MTT assay
Exponentially growing cells were seeded into a 96-well plate at
0.8 104 cells/well in triplicate. After incubation for 20 h, cells were
treated with increasing concentrations of SG, epirubicin, or pacli-
taxel for 48 h. At 44 h posttreatment, 20 mL of MTT (5 mg/mL) was
added to each well and incubated for 4 h. Then 150 mL of DMSOwas
added to every well to solubilize the formazan crystals formed by
viable cells, and the color intensity was measured at 550 nm with
an enzyme-linked immunosorbent assay plate reader (TECAN,
Männedorf, Switzerland).
2.5. Apoptosis assay
HeLa cells were cultured for 20 h and then treated with 80 mg/
mL SG with 0.5 mg/mL epirubicin or 10nM paclitaxel alone or
combined for 24 h. HeLa cells were harvested, washed with ice-
cold phosphate buffered saline (PBS), and stained with annexin
V/PI reagent as described previously [3]. The percentage of
annexin V (þ) cells was determined by ﬂow cytometry (Becton
Dickinson FACS Calibur Cytometer, San Jose, CA, USA). The per-
centage of annexin V (þ) cells indicates the frequency of total
apoptotic cells.
2.6. Cell-free caspase activity assay
As described [39], HeLa were treated and harvested. 50 mg
whole-cell lysates were incubated with 200nM Ac-LEHD-AFC (for
caspase-9), Ac-IETD-AFC (for caspase-8), and Ac-DEVD-AFC (for
caspase-3) in a reaction buffer containing 20mM
J Ginseng Res 2015;39:22e28244-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH
7.4,10mM dithiothreitol (DTT), 10% sucrose, 100mM NaCl, and 0.1%
3-((3-Cholamidopropyl)dimethylammonium)-1-propanesulfonate
(CHAPS) at 37C for 1 h. The reaction was monitored by ﬂuores-
cence excitation at 405 nm and emission at 505 nm.
2.7. Preparation of mitochondrial and cytosolic protein extracts
HeLa cells were treated and harvested. Mitochondria and cyto-
solic protein extracts were prepared using a Mitochondria Isolation
Kit (Pierce) according to the manufacturer’s instructions. Isolated
mitochondria were solubilized in a lysis buffer containing 20mM
TriseHCl (pH 7.5), 1% NP-40, 150mM NaCl, 0.5% deoxycholate, 0.1%
sodium dodecyl sulfate (SDS), 2mM MgCl2, 1mM ethylene glycol
tetraacetic acid (EGTA), 50mM b-glycerol phosphate, 25mM NaF,
1mM DTT, 1mM Na3VO4 with 2 mg/mL leupeptin, 2 mg/mL pep-
statin A, 2 mg/mL antipain, and 1mM phenylmethylsulfonyl ﬂuo-
ride (PMSF). The mitochondrial proteins were then subjected to
immunoblotting analysis using antibodies against Bax and Bak. The
cytosolic proteins were subjected to immunoblotting analysis using
antibody against cytochrome c.
2.8. Immunoblotting analysis
The treated cells were washed with ice-cold PBS and solubi-
lized in a lysis buffer containing 20mM Tris with a pH of 7.5, 2mM
MgCl2, 1mM DTT, 0.5% Triton X-100, 1mM EGTA, 25mM NaF, 1mM
Na3VO4, 50mM -glycerol phosphate, 2 mg/mL leupeptin, 2 mg/
mL pepstatin A, 2 mg/mL antipain, and 1mM PMSF. After incu-
bating on ice for 1 h, the insoluble materials were removed by
centrifugation at 14,000  g for 15 min. 50 mg of protein from each
sample was analyzed by SDS-polyacrylamide gel electrophoresis
(PAGE), followed by electrotransfer onto a PVDF membrane (Mil-
lipore). The membrane was blocked with 5% nonfat milk in PBS
with 0.1% Tween 20 and probed with the antibodies. The blots
were washed and incubated with a horseradish peroxidase-
coupled antimouse immunoglobulin G (IgG) or an antirabbit IgG
antibody (Pierce) followed by detection with an electrogenerated
chemiluminescence (ECL) revelation system (Bio-Rad).
2.9. Statistical analysis
All values are performed in triplicate and expressed as
mean  standard deviation with Microsoft Ofﬁce 2013 and imaged
with Sigmaplot 10 (Systat Software Inc, San Jose, CA, USA). A Stu-
dent t test was used for quantitative analysis, and the signiﬁcant
difference is shown as * p < 0.05, **p < 0.01, and ***p < 0.001.Fig. 1. High-performance liquid chromatography chr3. Results and Discussion
3.1. Analysis of SG extract
To determine the types of ginsenoside in SG, we analyzedMeOH
extract of SG by an analytical high-performance liquid chroma-
tography. As shown in Fig. 1, the amount of four main ginsenosides
in the total ginsenosides were 20(S)-Rg3 (11.33%), 20(R)-Rg3
(6.88%), Rk1 (16.72%), and Rg5 (11.97%).
3.2. Cytotoxic effect of SG on cancer cells
As shown in Fig. 1, the amount of ginsenoside Rg3, Rg5, and RK1
reached 50% of total ginsenosides in SG. A number of studies
showed that (20S) ginsenoside Rg3, Rg5, and RK1 inhibit cell
viability in various human cancer cells. We then examined whether
SG features cytotoxic activity in human cancer cells in human
cervical adenocarcinoma HeLa cells, human colon cancer SW111C
cells, and SW480 cells through an MTT assay. Fig. 2 illustrates that
SG exhibited a moderate cytotoxicity against the HeLa, SW111C,
and SW480 cells with IC50 values of 94 mg/mL, 78 mg/mL, and
224 mg/mL, respectively.
3.3. SG enhances the efﬁcacy of anticancer drugs epirubicin and
paclitaxel
To examine whether SG enhances the efﬁcacy of clinical anti-
cancer drugs, we determined the half maximal inhibitory concen-
tration (IC50) values of epirubicin and paclitaxel, either alone or
with a subtoxic concentration of SG, in the three cancer cell lines
(HeLa, SW111C, and SW480). Fig. 3 and Table 1 depict that the IC50
values markedly decreased with the addition of SG to epirubicin
and paclitaxel. The IC50 value of epirubicin in the HeLa cells was
1.05 mg/mL, which decreased to 0.15 mg/mL with the addition of
80 mg/mL SG. This result indicates that a subtoxic concentration of
SG signiﬁcantly increases the cytotoxic efﬁcacy of epirubicin. SG
exhibited similar potentiating activities on paclitaxel in all three
cancer cell lines.
3.4. SG helps induce strong apoptotic cell death in HeLa cells
To examine whether the role of SG in the cytotoxic effect of
epirubicin and paclitaxel was caused by the enhanced apoptosis,
we assessed the resulting apoptosis in the HeLa cells after separate
treatments with epirubicin and paclitaxel alone and after the
treatment with the combination of SG and the two drugs. The stage
of apoptosis was determined through annexin-V analysis. As shownomatogram of sun ginseng (SG) MeOH extract.
Fig. 2. Dose-dependent effects of sun ginseng (SG) on the cell viability of different human cancer cells. (A) Human cervical adenocarcinoma HeLa cells. (B and C) Human colon
cancer, SW111C, and SW480. These cells were treated with various concentrations of SG for 48 h. Cell viability was deﬁned by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT) assay. The results represent three independent experiments performed in triplicate. The values from each treatment are expressed as a percentage relative to the
control (100%). Each point represents the mean  standard deviation. A Student t test was used for quantitative analysis, and the signiﬁcant difference is shown as * p < 0.05,
**p < 0.01, and ***p < 0.001 compared with those not treated.
Fig. 3. Sun ginseng (SG) enhances the antiproliferative activities of epirubicin and paclitaxel. HeLa, SW111C, and SW480 cells were treated with different concentrations of epi-
rubicin or paclitaxel with or without different concentrations of SG for 48 h. Cell viability was estimated by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT)
assay and expressed as the percentage of viable cells in the treated and controlled samples. Data are presented as mean  standard deviation of experiments performed in triplicate.
A Student t test was used for quantitative analysis, and the signiﬁcant difference is shown as * p < 0.05, **p < 0.01, and ***p < 0.001.
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Table 1
The resulting half maximal inhibitory concentration values from the 48-h drug









HeLa 1.05 0.15 12.57 1.9
SW111C 1.84 0.30 >100 1.92
SW480 3.32 0.53 >100 0.99
J Ginseng Res 2015;39:22e2826in Fig. 4A and C, the percentage of apoptotic cells was considerably
higher in the cotreated cells than in the epirubicin- and paclitaxel-
treated cells. To determine the activation of caspase in the cells, we
detected the PARP cleavage through immunoblotting analysis.
Fig. 4B and D show that PARP was cleaved to yield an 85-kD frag-
ment in the drug-treated cells and that the amount of the cleaved
85-kD fragment was more signiﬁcant in the co-treated cells than in
the epirubicin- and paclitaxel-treated cells. On the basis of these
results, we suggest that SG enhances the anticancer activities of
epirubicin and paclitaxel through caspase-associated apoptosis.
3.5. SG enhances apoptosis via the mitochondrial pathway
To elucidate the initiation event of apoptosis, we inspected the
activation kinetics of the two initiator caspases, namely, caspase-8
and -9, and the effector caspases, caspase-3/-7. As shown in Fig. 5,
the activities of caspase-9 and -3/-7 greatly increased in the
cotreated cells than in the epirubicin- and paclitaxel-treated cells.
By contrast, the activity of caspase-8 did not show any change in all
cells. We then determined the cleavage of caspase-9 and -8. Spe-
ciﬁcally, we examined the proteolytic activation of these caspases
through immunoblotting analysis. Apparent cleavage was observed
in caspase-9 but not in caspase-8. The amounts of the active form ofFig. 4. Apoptosis was synergistically induced by sun ginseng (SG) and epirubicin or paclitax
with the combination of 0.5 mg/mL epirubicin and 80 mg/mL SG for 24 h. (C and D) HeLa cells
and 80 mg/mL SG for 24 h. (A and C) Cells were stained with annexin V-FITC and PI and analyz
performed in triplicate. (B and D) The equal amounts of cell extracts were resolved by sodiu
using speciﬁc antibodies against poly (adenosine diphosphate-ribose) polymerase and a-tuthe cleaved caspase-9 were higher in the cotreated cells than in the
epirubicin- and paclitaxel-treated cells. The data suggest that epi-
rubicin and paclitaxel-induced apoptosis might be potentiated by
SG via the intrinsic apoptosis pathway in HeLa cells.
3.6. Apoptosis of SG-enhanced HeLa cells mediated through
cytochrome C release
The release of mitochondrial cytochrome c is the crucial event in
caspase-9 activation [40]. The family members of the Bcl-2 family,
namely, Bax and Bak, serve as an essential gateway for the release
of cytochrome c [5,41]. Fig. 6 shows that cytochrome c appeared in
cytosol after the cell was treated with the two drugs; the levels of
this protein in the cytosol were much higher in the SG and epi-
rubicin or paclitaxel-treated HeLa cells than in the epirubicin- and
paclitaxel-treated cells. Similarly, the levels of Bax and Bak in the
mitochondria were markedly increased in the epirubicin- and
paclitaxel-treated cells, but this increase was more signiﬁcant in
the cotreated groups (Fig. 7). Moreover, the increase of Bax and Bak
in the mitochondria upon drug treatment conformed well to the
release of the enhanced cytochrome c in the apoptotic cells. How-
ever, no evident changes were observed in Bax or Bak in the whole-
cell lysates. These results imply that the increased regulation of the
released cytochrome c that was observed in the co-treated HeLa
cells resulted from the enhanced translocation of Bax and Bak
proteins.
The induction of apoptosis in cancer cells is a staple killing
mechanism for most antitumor therapies [2]. The cotreatment of
anticancer reagents has been shown to be advantageous in malig-
nancies that still partially respond to epirubicin or paclitaxel
treatment because they may help amplify weak death signals. In
this study, SG markedly potentiated epirubicin- or paclitaxel-
induced cancer cell death possibly because of the increase in theel in HeLa cells. (A and B) HeLa cells were treated with 0.5 mg/mL epirubicin alone and
were treated with 10nM paclitaxel alone and with the combination of 10nM paclitaxel
ed by ﬂow cytometry. Data are presented as mean  standard deviation of experiments
m dodecyl sulfate polyacrylamide gel electrophoresis and analyzed by immunoblotting
bulin.
Fig. 5. Sun ginseng (SG) and epirubicin or paclitaxel synergistically acted to induce the activation of caspase-9 and -3 in HeLa cells. (AeD) HeLa cells were treated with 0.5 mg/mL
epirubicin alone and with the combination of 0.5 mg/mL epirubicin and 80 mg/mL SG for 24 h. (EeH) HeLa cells were treated with 10nM paclitaxel alone and with the combination of
10nM paclitaxel and 80 mg/mL SG for 24 h. (AeC, EeG) Cell-free caspases-3, -9, and -8 activities were analyzed by using speciﬁc substrates (Ac-DEVD-AFC, Ac-LEHD-AFC, and Ac-
IETD-AFC, respectively). Data are presented as mean  standard deviation of experiments performed in triplicate. A Student t test was used for quantitative analysis, and the
signiﬁcant difference is shown as * p < 0.05, **p < 0.01, and ***p < 0.001. (D, H) Cell lysates were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis and
analyzed by immunoblotting using speciﬁc antibodies against caspase-8, caspase-9, and a-tubulin.
Fig. 6. Sun ginseng (SG) and epirubicin or paclitaxel synergistically induced the mitochondrial membrane depolarization and cytochrome c release in HeLa cells. (A) HeLa cells were
treated with 0.5 mg/mL epirubicin alone and with the combination of 0.5 mg/mL epirubicin and 80 mg/mL SG for 24 h. (B) HeLa cells were treated with 10nM paclitaxel alone and
with the combination of 10nM paclitaxel and 80 mg/mL SG for 24 h. The equal amounts of cytosol fractions from the treated or untreated HeLa cells were resolved by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (15%) and analyzed by immunoblotting using speciﬁc antibodies against cytochrome c and a-tubulin. Representative results from one of
the three independent experiments are shown.
Fig. 7. Bak and Bax were translocated to the mitochondria in the sun ginseng (SG) and epirubicin or paclitaxel co-treated HeLa cells. (A and B) HeLa cells were treated with 0.5 mg/
mL epirubicin alone and with the combination of 0.5 mg/mL epirubicin and 80 mg/mL SG for 24 h. (C and D) HeLa cells were treated with 10nM paclitaxel alone and with the
combination of 10nM paclitaxel and 80 mg/mL SG for 24 h. The equal amounts of the mitochondrial fraction of proteins (A and C) and the total cell lysates (B and D) were resolved by
sodium dodecyl sulfate polyacrylamide gel electrophoresis (15%) and analyzed by immunoblotting using antibodies against Bax, Bak, COXII, and a-tubulin. COXII and a-tubulin acted
as loading controls. Representative results from one of the three independent experiments are shown.
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J Ginseng Res 2015;39:22e2828release of cytochrome c and the activation of caspases-9 and -3.
Thus, cotreating cancer cells with SG and clinical drugs could be a
novel strategy for enhancing the efﬁcacy of current chemother-
apies. The development of SG as a new adjuvant drug for cancer
therapy also shows great potential.
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